[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0213696A - Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome - Google Patents

Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome

Info

Publication number
BR0213696A
BR0213696A BR0213696-1A BR0213696A BR0213696A BR 0213696 A BR0213696 A BR 0213696A BR 0213696 A BR0213696 A BR 0213696A BR 0213696 A BR0213696 A BR 0213696A
Authority
BR
Brazil
Prior art keywords
acetylcholine receptor
treatment
nicotinic acetylcholine
restless leg
leg syndrome
Prior art date
Application number
BR0213696-1A
Other languages
Portuguese (pt)
Inventor
Mario David Saltarelli
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0213696A publication Critical patent/BR0213696A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

"AGONISTAS DO RECEPTOR DE ACETILCOLINA NICOTìNICOS NO TRATAMENTO DA SìNDROME DE PERNAS INQUIETAS". A presente invenção refere-se ao uso de agonistas de receptores de acetilcolina nicotínicos para tratamento de síndrome de pernas inquietas (RLS). Adicionalmente, a invenção refere-se ao uso de um agonista de receptor de acetilcolina nicotínico na fabricação de um medicamento para tratamento de síndrome de pernas inquietas (RLS). A presente invenção também refere-se a uma composição farmacêutica para tratamento de síndrome de pernas inquietas (RLS) que contém um agonista de receptor de acetilcolina nicotínico."NICOTINIC ACETILCOLINE RECEPTOR AGONISTS IN THE TREATMENT OF REQUIRED LEGS SYNDROME". The present invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless leg syndrome (RLS). Additionally, the invention relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for treating restless leg syndrome (RLS). The present invention also relates to a pharmaceutical composition for treating restless leg syndrome (RLS) which contains a nicotinic acetylcholine receptor agonist.

BR0213696-1A 2001-10-31 2002-10-21 Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome BR0213696A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33481001P 2001-10-31 2001-10-31
US33585801P 2001-11-26 2001-11-26
PCT/IB2002/004379 WO2003037329A1 (en) 2001-10-31 2002-10-21 Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome

Publications (1)

Publication Number Publication Date
BR0213696A true BR0213696A (en) 2004-10-26

Family

ID=26989404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213696-1A BR0213696A (en) 2001-10-31 2002-10-21 Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome

Country Status (14)

Country Link
EP (1) EP1439836A1 (en)
JP (1) JP2005507411A (en)
KR (1) KR20050038583A (en)
CN (1) CN1568184A (en)
BR (1) BR0213696A (en)
CA (1) CA2460118A1 (en)
CZ (1) CZ2004524A3 (en)
HU (1) HUP0401967A2 (en)
IL (1) IL160967A0 (en)
MX (1) MXPA04002539A (en)
PL (1) PL370549A1 (en)
SK (1) SK1912004A3 (en)
TW (1) TW200300139A (en)
WO (1) WO2003037329A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
NZ579515A (en) 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US7803839B2 (en) 2005-10-07 2010-09-28 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN101605540A (en) 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 Use the method for mek inhibitor
JP6272857B2 (en) * 2012-07-27 2018-01-31 ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Enhanced brain bioavailability of galantamine and transmucosal administration of lipophilic prodrugs with selected formulations
ES2880399T3 (en) 2012-07-27 2021-11-24 Neurodyn Life Sciences Inc Improved cerebral bioavailability of galantamine through selected formulations and transmucosal administration of lipophilic prodrugs
MA38085B1 (en) 2012-10-12 2018-11-30 Exelixis Inc New process for the production of compounds for use in the treatment of cancer
WO2016188932A2 (en) 2015-05-22 2016-12-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Combination compositions and their use in methods for treating obesity and obesity-related disorders
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. Method and compositions for treating restless legs syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020335A (en) * 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
IL138917A0 (en) * 1998-04-29 2001-11-25 Pfizer Prod Inc Aryl fused azapolycyclic compounds

Also Published As

Publication number Publication date
PL370549A1 (en) 2005-05-30
KR20050038583A (en) 2005-04-27
CZ2004524A3 (en) 2004-07-14
HUP0401967A2 (en) 2005-01-28
WO2003037329A1 (en) 2003-05-08
MXPA04002539A (en) 2004-05-31
JP2005507411A (en) 2005-03-17
IL160967A0 (en) 2004-08-31
EP1439836A1 (en) 2004-07-28
TW200300139A (en) 2003-05-16
SK1912004A3 (en) 2004-09-08
CN1568184A (en) 2005-01-19
CA2460118A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
DK1531832T3 (en) Therapeutic compositions for use in prophylaxis or treatment of diarrhea
BR9910583A (en) Non-substituted aminotetralins as binders for the neuropeptide receptor y5 useful in the treatment of obesity and other disorders
BR0210568A (en) Conjugate, Use of a Conjugate, Pharmaceutical Composition, and, Method for Treating Cancer in a Mammal
PT1267866E (en) RESPIRATORY DISEASE TREATMENT
BRPI0007487B8 (en) diphenyl-ureas substituted with w-carboxy-aryls as raf kinase inhibitors
GB0008269D0 (en) Combination chemotherapy
BR0013355A (en) Drug treatment for restless leg syndrome
BRPI0618479A2 (en) pyrrolpyridines pharmaceutical composition containing them
BRPI0416752B8 (en) pharmaceutical composition, use of one or more compounds, and compounds
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
ECSP034732A (en) DERIVATIVE OF PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES
GEP20104962B (en) Fused heterocyclic compounds
BRPI0408681A (en) compounds, pharmaceutical compositions, use of a 1,2,3,4-tetrahydroisoquinoline derivative, method for treating or preventing disease, process for the manufacture of pharmaceutical compositions, and use of one or more compounds
UA83659C2 (en) P2x7 receptor antagonists and their use, pharmaceutical composition based thereon, process for the preparation thereof (variants)
NO20084752L (en) Conjugates of aziridinayl epothilone analogs and pharmaceutical compositions containing them
BR0209312A (en) Food composition of canola protein isolate
BR0209127A (en) compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
DK1675591T3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter reuptake inhibitor and an acetylcholinesterase inhibitor
BRPI0509074A (en) pharmaceutical compositions comprising thyroid receptor agonists
DK1063995T3 (en) Combination to treat alcohol dependence containing an opioid antagonist and an NMDA receptor complex modulator
BRPI0409742A (en) use of an anti-angiogenic agent, in combination with a src family inhibitor of non-receptor tyrosine kinases, combination product, and pharmaceutical composition
BR0213696A (en) Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome
BR0313220A (en) Coating film for tablets and capsules
PT1358177E (en) TREATMENT OF AFFECTIVE DISORDERS THROUGH THE COMBINED ACTION OF AN AGNIST OF THE NICOTYNIC RECIPIENT AND A MANOAMINERGIC SUBSTANCE
DK1651270T3 (en) Medications for inhalation comprising betamimetics and an anticholinergic

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.